Literature DB >> 24470276

Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine.

Hung Fu Tseng1, D Scott Schmid, Rafael Harpaz, Philip LaRussa, Nancy J Jensen, Pierre Rivailler, Kay Radford, Jennifer Folster, Steven J Jacobsen.   

Abstract

We report the first laboratory-documented case of herpes zoster caused by the attenuated varicella zoster virus (VZV) contained in Zostavax in a 68-year-old immunocompetent adult with strong evidence of prior wild-type VZV infection. The complete genome sequence of the isolate revealed that the strain carried 15 of 42 (36%) recognized varicella vaccine-associated single-nucleotide polymorphisms, including all 5 of the fixed vaccine markers present in nearly all of the strains in the vaccine. The case of herpes zoster was relatively mild and resolved without complications.

Entities:  

Keywords:  adult vaccination; herpes zoster; varicella zoster virus

Mesh：

Substances：

Year:  2014        PMID： 24470276      PMCID： PMC3967828          DOI： 10.1093/cid/ciu058

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  16 in total

Review 1.  Experience with live-attenuated varicella-zoster vaccines.

Authors:  P LaRussa
Journal:  Contrib Microbiol       Date:  1999

2.  Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR.

Authors:  V N Loparev; T Argaw; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

3.  Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates.

Authors:  T Argaw; J I Cohen; M Klutch; K Lekstrom; T Yoshikawa; Y Asano; P R Krause
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

Review 4.  The safety profile of varicella vaccine: a 10-year review.

Authors:  Susan A Galea; Ann Sweet; Paul Beninger; Sharon P Steinberg; Philip S Larussa; Anne A Gershon; Robert G Sharrar
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

5.  Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009.

Authors:  Sheila Weinmann; Colleen Chun; D Scott Schmid; Michelle Roberts; Meredith Vandermeer; Karen Riedlinger; Stephanie R Bialek; Mona Marin
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

6.  Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children.

Authors:  Anne A Gershon; Jason Chen; Larry Davis; Clarissa Krinsky; Robert Cowles; Ross Reichard; Michael Gershon
Journal:  Trans Am Clin Climatol Assoc       Date:  2012

7.  Predicting the functional effect of amino acid substitutions and indels.

Authors:  Yongwook Choi; Gregory E Sims; Sean Murphy; Jason R Miller; Agnes P Chan
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 8.  A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008.

Authors:  Judith Breuer; Charles Grose; Peter Norberg; Graham Tipples; D Scott Schmid
Journal:  J Gen Virol       Date:  2010-01-13       Impact factor: 3.891

9.  Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.

Authors:  Sinéad M Langan; Liam Smeeth; David J Margolis; Sara L Thomas
Journal:  PLoS Med       Date:  2013-04-09       Impact factor: 11.069

10.  Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans.

Authors:  Daniel P Depledge; Samit Kundu; Nancy J Jensen; Eleanor R Gray; Meleri Jones; Sharon Steinberg; Anne Gershon; Paul R Kinchington; D Scott Schmid; Francois Balloux; Richard A Nichols; Judith Breuer
Journal:  Mol Biol Evol       Date:  2013-10-25       Impact factor: 16.240
View more
  22 in total

1.  Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons.

Authors:  Nancy J Jensen; Pierre Rivailler; Hung Fu Tseng; Mark L Quinlivan; Kay Radford; Jennifer Folster; Rafael Harpaz; Philip LaRussa; Steven Jacobsen; D Scott Schmid
Journal:  J Gen Virol       Date:  2017-06-14       Impact factor: 3.891

2.  Herpes Zoster Caused by Zoster Vaccine in an Immunocompetent Patient; Restless Leg Syndrome Due to the Combination of Venlafaxine and Quetiapine; SSRIs and the Risk of Upper Gastrointestinal Bleeding; Minocycline-Induced Cutaneous Polyarteritis Nodosa.

Authors:  Michael A Mancano
Journal:  Hosp Pharm       Date:  2014-07

Review 3.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).

Authors:  G Redelman-Sidi; O Michielin; C Cervera; C Ribi; J M Aguado; M Fernández-Ruiz; O Manuel
Journal:  Clin Microbiol Infect       Date:  2018-02-07       Impact factor: 8.067

4.  Varicella Zoster Virus and Giant Cell Arteritis.

Authors:  Anne A Gershon; Michael Gershon
Journal:  J Infect Dis       Date:  2016-03-31       Impact factor: 5.226

Review 5.  Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.

Authors:  English D Willis; Meredith Woodward; Elizabeth Brown; Zoran Popmihajlov; Patricia Saddier; Paula W Annunziato; Neal A Halsey; Anne A Gershon
Journal:  Vaccine       Date:  2017-11-22       Impact factor: 3.641

Review 6.  Vaccination for quality of life: herpes-zoster vaccines.

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Aging Clin Exp Res       Date:  2019-10-23       Impact factor: 3.636

7.  ORF7 of Varicella-Zoster Virus Is Required for Viral Cytoplasmic Envelopment in Differentiated Neuronal Cells.

Authors:  Hai-Fei Jiang; Wei Wang; Xuan Jiang; Wen-Bo Zeng; Zhang-Zhou Shen; Yi-Ge Song; Hong Yang; Xi-Juan Liu; Xiao Dong; Jing Zhou; Jin-Yan Sun; Fei-Long Yu; Lin Guo; Tong Cheng; Simon Rayner; Fei Zhao; Hua Zhu; Min-Hua Luo
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

8.  Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge.

Authors:  Christine Meyer; Flora Engelmann; Nicole Arnold; David L Krah; Jan ter Meulen; Kristen Haberthur; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

9.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

10.  Varicella in Tshuapa Province, Democratic Republic of Congo, 2009-2014.

Authors:  Jessica Leung; Andrea M McCollum; Kay Radford; Christine Hughes; Adriana S Lopez; Sarah Anne J Guagliardo; Beatrice Nguete; Toutou Likafi; Joelle Kabamba; Jean Malekani; Robert Shongo Lushima; Elisabeth Pukuta; Stomy Karhemere; Jean Jacques Muyembe Tamfum; Mary G Reynolds; Emile Wemakoy Okitolonda; D Scott Schmid; Mona Marin
Journal:  Trop Med Int Health       Date:  2019-05-22       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.